BioMarin Pharmaceutical | BMRN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Bayer EUR 10.33B 126M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12